# A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

> **NCT00661609** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 54 (actual)

## Conditions studied

- Bladder Cancer
- Transitional Cell Bladder Cancer
- Urethra Cancer
- Ureter Cancer
- Renal Pelvis Cancer

## Interventions

- **DRUG:** AZD4877

## Key facts

- **NCT ID:** NCT00661609
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2009-05
- **Final completion:** 2009-12
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2011-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00661609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00661609, "A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00661609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*